A "Window of Therapeutic Opportunity" for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019.
T cell
coronavirus
cytokine storm
immune activation
innate and adaptive immune response
tocilizumab (IL-6 inhibitor)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
06
2020
accepted:
21
09
2020
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
11
11
2020
Statut:
epublish
Résumé
The effects of cytokine inhibition in the different phases of the severe coronavirus disease 2019 (COVID-19) are currently at the center of intense debate, and preliminary results from observational studies and case reports offer conflicting results thus far. The identification of the correct timing of administration of anti-cytokine therapies and other immunosuppressants in COVID-19 should take into account the intricate relationship between the viral burden, the hyperactivation of the innate immune system and the adaptive immune dysfunction. The main challenge for effective administration of anti-cytokine therapy in COVID-19 will be therefore to better define a precise "window of therapeutic opportunity." Only considering a more specific set of criteria able to integrate information on direct viral damage, the cytokine burden, and the patient's immune vulnerability, it will be possible to decide, carefully balancing both benefits and risks, the appropriateness of using immunosuppressive drugs even in patients affected primarily by an infectious disease.
Identifiants
pubmed: 33123149
doi: 10.3389/fimmu.2020.572635
pmc: PMC7572850
doi:
Substances chimiques
Cytokines
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
572635Informations de copyright
Copyright © 2020 De Stefano, Bobbio-Pallavicini, Manzo, Montecucco and Bugatti.
Références
J Infect. 2020 Oct;81(4):e11-e17
pubmed: 32652164
Lancet Infect Dis. 2020 Jun;20(6):635-636
pubmed: 32224308
Infect Dis Ther. 2020 Sep 2;:
pubmed: 32880102
Clin Infect Dis. 2020 May 19;:
pubmed: 32427279
Clin Infect Dis. 2020 Jul 04;:
pubmed: 32621739
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Annu Rev Pathol. 2018 Jan 24;13:27-49
pubmed: 28934563
Lancet Rheumatol. 2020 Oct;2(10):e594-e602
pubmed: 32864628
Cell Mol Immunol. 2020 Apr 7;:
pubmed: 32265513
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
J Med Virol. 2005 Feb;75(2):185-94
pubmed: 15602737
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Cell Host Microbe. 2016 Feb 10;19(2):181-93
pubmed: 26867177
Autoimmun Rev. 2020 Jul;19(7):102569
pubmed: 32376394
Nat Med. 2020 Jun;26(6):842-844
pubmed: 32398875
Cancer J. 2014 Mar-Apr;20(2):119-22
pubmed: 24667956
Autoimmun Rev. 2020 Jul;19(7):102562
pubmed: 32376400
Emerg Microbes Infect. 2020 Dec;9(1):469-473
pubmed: 32102625
J Infect. 2020 Jul;81(1):e13-e20
pubmed: 32283144
EClinicalMedicine. 2020 Aug;25:100459
pubmed: 32838235
J Hosp Med. 2020 Aug;15(8):489-493
pubmed: 32804611
Lancet Rheumatol. 2020 Oct;2(10):e603-e612
pubmed: 32838323
Autoimmun Rev. 2020 Jul;19(7):102567
pubmed: 32376392
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532
pubmed: 32359035
Emerg Microbes Infect. 2020 Dec;9(1):761-770
pubmed: 32228226
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
Autoimmun Rev. 2020 Jul;19(7):102564
pubmed: 32376396
Cell Host Microbe. 2020 Jun 10;27(6):863-869
pubmed: 32464098
J Infect. 2020 Oct;81(4):647-679
pubmed: 32592703
Microorganisms. 2020 May 09;8(5):
pubmed: 32397399
Lancet Microbe. 2020 Oct;1(6):e245-e253
pubmed: 32844161
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Lancet Respir Med. 2020 Aug 27;:
pubmed: 32861275
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Br J Haematol. 2016 Jan;172(1):11-22
pubmed: 26560054
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
Nat Rev Immunol. 2020 May;20(5):269-270
pubmed: 32273594
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Lancet Rheumatol. 2020 Jul;2(7):e393-e400
pubmed: 32835245
PLoS Pathog. 2013 Feb;9(2):e1003188
pubmed: 23468627
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Arthritis Rheumatol. 2017 Jun;69(6):1135-1143
pubmed: 28217930
J Infect Dis. 2005 May 15;191(10):1697-704
pubmed: 15838797
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Autoimmun Rev. 2020 Jun;19(6):102536
pubmed: 32251718
J Immunol. 2020 Jul 15;205(2):307-312
pubmed: 32493814
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2
pubmed: 32407669
Front Microbiol. 2019 May 10;10:1057
pubmed: 31134045
Ann Rheum Dis. 2020 Oct;79(10):1277-1285
pubmed: 32620597
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
J Clin Virol. 2020 Aug;129:104444
pubmed: 32570043
Arthritis Rheumatol. 2014 Sep;66(9):2613-20
pubmed: 24782338
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Chest. 2020 Oct;158(4):1397-1408
pubmed: 32553536
Curr Opin Crit Care. 2019 Feb;25(1):12-20
pubmed: 30531367
Ann Rheum Dis. 2020 Sep;79(9):1152-1155
pubmed: 32719039
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
N Engl J Med. 2020 Jul 17;:
pubmed: 32678530
Immunol Rev. 2020 Jul;296(1):205-219
pubmed: 32658335
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Hematol Oncol Clin North Am. 2015 Oct;29(5):927-41
pubmed: 26461152
Lancet Rheumatol. 2020 Jun;2(6):e325-e331
pubmed: 32501454
Nature. 2020 Jul;583(7816):437-440
pubmed: 32434211